Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.31 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13298442 | 1.00 | ESR1 (0.40) | ESR1ESR2NR1H3ACHEDHCR24 | |
| SCHEMBL17299641 | 0.89 | ESR1 (0.51) | ESR1ESR2NR1H3ACHE | |
| SCHEMBL17299275 | 0.89 | ESR1 (0.51) | ESR1ESR2NR1H3ACHE | |
| SCHEMBL17299270 | 0.89 | ESR1 (0.51) | ESR1ESR2NR1H3ACHE | |
| SCHEMBL17299259 | 0.89 | ESR1 (0.51) | ESR1ESR2NR1H3ACHE | |
| SCHEMBL15045295 | 0.89 | ESR1 (0.51) | ESR1ESR2NR1H3ACHE | |
| SCHEMBL13298432 | 0.89 | ESR1 (0.51) | ESR1ESR2NR1H3ACHE | |
| SCHEMBL15045291 | 0.83 | ESR1 (0.39) | ESR1ESR2ACHE | |
| SCHEMBL17299276 | 0.83 | ESR1 (0.39) | ESR1ESR2ACHE | |
| SCHEMBL17299260 | 0.83 | ESR1 (0.39) | ESR1ESR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344421-A1 | Versatile and Functionalised Intermediates for the Synthesis of Vitamin D and Novel Vitamin D Derivatives | ENDOTHERM GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344421-A1 | Versatile and Functionalised Intermediates for the Synthesis of Vitamin D and Novel Vitamin D Derivatives | VDR, CYP24A1, CYP2R1 | ESR1 615/4885ESR2 441/4885NR1H3 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.